TRANSPOSASES IN ETOPOSIDE RESISTANCE
依托泊苷抗性中的转座酶
基本信息
- 批准号:8192937
- 负责人:
- 金额:$ 27.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-06-02 至 2013-05-31
- 项目状态:已结题
- 来源:
- 关键词:Antineoplastic AgentsApoptosisCancer PatientCell Cycle ArrestCell ProliferationCell SurvivalCell divisionCellsChromatidsChromosomesCleaved cellClinicalConsensusDNADNA DamageDNA Double Strand BreakDNA RepairDNA ligase IVDNA repair proteinDrug Delivery SystemsEnzymesEtoposideGenerationsGenomic InstabilityGerm cell tumorHealthHistonesHumanIn VitroInvestigationMalignant NeoplasmsMalignant neoplasm of ovaryMalignant neoplasm of testisMediatingMitosisMovementNBS1 geneNeurofibrillary TanglesNonhomologous DNA End JoiningOrganismOutcomePathway interactionsPatientsPharmaceutical PreparationsPhosphorylationProteinsRelative (related person)ResistanceRiskRoleSET DomainSamplingScreening procedureSignal TransductionSiteStructureSuperhelical DNATertiary Protein StructureTestingTopoisomerase IITopoisomerase II inhibitionTopoisomerase-II InhibitorTransposasebasecancer cellcancer typeclinically relevantendonucleaseexperiencehistone methyltransferaseimprovedin vivoinhibitor/antagonistleukemia/lymphomalung small cell carcinomaneoplasticnovelnucleasepreventrepairedrepositoryresponsesmall moleculetumorvirtual
项目摘要
DESCRIPTION (provided by applicant): Transposase activity was thought to be extinct in humans because DNA movement can be deleterious in higher organisms, resulting in genomic instability and perhaps malignancy. However, we isolated a human transposase protein termed Metnase that had histone methylase and non-homologous end-joining (NHEJ) DNA repair activity. It was found to interact with DNA Ligase IV, consistent with its NHEJ repair activity. Metnase also was an endonuclease preferential for supercoiled DNA. We therefore explored Metnase's role in decatenating replicated chromatids. Metnase interacted with Topoisomerase II (Topo II ), the critical decatenating enzyme, and enhanced its activity in DNA decatenation, both in vitro and intracellularly. The nuclease activity within the transposase domain of Metnase was required for full enhancement of Topo II decatenating activity. Metnase improved the rate at which Topo II decatenated DNA, and increased the ability of Topo II to resist the decatenation inhibitor ICRF-193. The finding that Metnase improved Topo II resistance to ICRF-193 stimulated an investigation into whether it could mediate resistance to the clinically relevant Topo II inhibitor etoposide. We found that Metnase prevented inhibition of Topo II decatenation by etoposide in vitro, and mediated cellular resistance to etoposide, promoting proliferation in the presence of etoposide. Metnase also promoted a more rapid clearance of etoposide-induced DSB. Thus, Metnase appeared to mediate resistance to etoposide-induced DNA damage and cell cycle arrest. This is a novel mechanism of etoposide resistance that is unexplored. This application proposes to define the mechanism by which Metnase mediates resistance to etoposide by asking three questions: 1) What are the upstream signals that regulate the ability of Metnase to reduce etoposide DSBs? 2) What is the downstream pathway by which Metnase reduces etoposide DSBs? 3) Do Metnase levels predic clinical resistance to etoposide in human malignancy?
描述(由申请人提供):转座酶活性被认为在人类中已经灭绝,因为DNA运动在高等生物中可能是有害的,导致基因组不稳定和可能的恶性肿瘤。然而,我们分离出一种名为Metnase的人转座酶蛋白,它具有组蛋白甲基化酶和非同源末端连接(NHEJ) DNA修复活性。发现它与DNA连接酶IV相互作用,与其NHEJ修复活性一致。甲基化酶也是一种优先用于超卷曲DNA的内切酶。因此,我们探讨了甲基化酶在消去复制染色单体中的作用。Metnase与Topoisomerase II (Topo II)相互作用,增强了其在体外和细胞内DNA十烷化的活性。在Metnase转座酶结构域内的核酸酶活性是Topo II十烷化活性充分增强的必要条件。Metnase提高了Topo II对DNA进行十烷化的速率,并增强了Topo II抵抗十烷化抑制剂ICRF-193的能力。Metnase可改善Topo II对ICRF-193的耐药性,这一发现激发了对其是否介导对临床相关Topo II抑制剂依托泊苷的耐药性的研究。我们发现Metnase在体外阻止依托泊苷对Topo II十烷磺酸的抑制,并介导细胞对依托泊苷的抗性,促进依托泊苷存在下的增殖。Metnase也促进了依托泊苷诱导的DSB更快的清除。因此,Metnase似乎介导了对依托泊苷诱导的DNA损伤和细胞周期阻滞的抗性。这是一种尚未探索的依托泊苷耐药新机制。本申请通过提出三个问题来定义Metnase介导对依托泊苷抗性的机制:1)调节Metnase减少依托泊苷dsb能力的上游信号是什么?2) Metnase还原依托泊苷dsb的下游途径是什么?3) Metnase水平是否预示人类恶性肿瘤对依托泊苷的临床耐药?
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robert A Hromas其他文献
Robert A Hromas的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Robert A Hromas', 18)}}的其他基金
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Milk fat globule-EGF factor 8 and hepatocyte apoptosis-induced liver wound healing response
乳脂肪球-EGF因子8与肝细胞凋亡诱导的肝脏创面愈合反应
- 批准号:
10585802 - 财政年份:2023
- 资助金额:
$ 27.12万 - 项目类别:
Development of an apoptosis biosensor for monitoring of breast cancer
开发用于监测乳腺癌的细胞凋亡生物传感器
- 批准号:
10719415 - 财政年份:2023
- 资助金额:
$ 27.12万 - 项目类别:
Interrogating the Fgl2-FcγRIIB axis on CD8+ T cells: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
询问 CD8 T 细胞上的 Fgl2-FcγRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10605856 - 财政年份:2023
- 资助金额:
$ 27.12万 - 项目类别:
Novel targeted therapy for FGFR inhibitor-resistant urothelial cancer and apoptosis based therapy for urothelial cancer
FGFR抑制剂耐药性尿路上皮癌的新型靶向治疗和基于细胞凋亡的尿路上皮癌治疗
- 批准号:
23K08773 - 财政年份:2023
- 资助金额:
$ 27.12万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanistic analysis of apoptosis induction by HDAC inhibitors in head and neck cancer
HDAC抑制剂诱导头颈癌凋亡的机制分析
- 批准号:
23K15866 - 财政年份:2023
- 资助金额:
$ 27.12万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
探究 Fgl2-FcgRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10743485 - 财政年份:2023
- 资助金额:
$ 27.12万 - 项目类别:
Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
研究细胞凋亡抗性和肿瘤环境对骶尾部畸胎瘤发生和维持的作用
- 批准号:
10749797 - 财政年份:2023
- 资助金额:
$ 27.12万 - 项目类别:
The effects of glucose on immune cell apoptosis and mitochondrial membrane potential and the analysis of its mechanism by which glucose might modulate the immune functions.
葡萄糖对免疫细胞凋亡和线粒体膜电位的影响及其调节免疫功能的机制分析。
- 批准号:
22K09076 - 财政年份:2022
- 资助金额:
$ 27.12万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION
P53 信号传导、细胞凋亡和肿瘤抑制中的 XAF1
- 批准号:
10583516 - 财政年份:2022
- 资助金额:
$ 27.12万 - 项目类别:
Role of Thioredoxin system in regulation of autophagy-apoptosis cross talk in neurons: Uncovering Novel Molecular Interactions.
硫氧还蛋白系统在神经元自噬-凋亡串扰调节中的作用:揭示新的分子相互作用。
- 批准号:
RGPIN-2019-05371 - 财政年份:2022
- 资助金额:
$ 27.12万 - 项目类别:
Discovery Grants Program - Individual